SYNCOM FORMULATIONS (INDIA)
Back to Cashflow Statement
|
SYNCOM FORMULATIONS (INDIA) Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2017 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹-68 Cr | ₹-15 Cr | ₹35 Cr | ₹8.29 Cr | ₹4.67 Cr |
What is the latest Cash Flow from Financing Activities ratio of SYNCOM FORMULATIONS (INDIA) ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2025 | ₹-68 Cr |
| Mar2024 | ₹-15 Cr |
| Mar2023 | ₹35 Cr |
| Mar2022 | ₹8.29 Cr |
| Mar2017 | ₹4.67 Cr |
How is Cash Flow from Financing Activities of SYNCOM FORMULATIONS (INDIA) Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2025 | ₹-68 Cr | Negative | |
| Mar2024 | ₹-15 Cr | Negative | |
| Mar2023 | ₹35 Cr | 321.95 | |
| Mar2022 | ₹8.29 Cr | 77.66 | |
| Mar2017 | ₹4.67 Cr | - | |
Compare Cash Flow from Financing Activities of peers of SYNCOM FORMULATIONS (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SYNCOM FORMULATIONS (INDIA) | ₹1,274.6 Cr | -5.6% | 4.6% | -22.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹407,827.0 Cr | -0.5% | 1.8% | -2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹163,363.0 Cr | -0.3% | -1.3% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹144,193.0 Cr | 4.4% | 6% | 27.7% | Stock Analytics | |
| CIPLA | ₹109,519.0 Cr | 1% | -3% | -8.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹105,940.0 Cr | 1.1% | 8% | 3.8% | Stock Analytics | |
SYNCOM FORMULATIONS (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SYNCOM FORMULATIONS (INDIA) | -5.6% |
4.6% |
-22.2% |
| SENSEX | -0.9% |
-0.1% |
7% |
You may also like the below Video Courses